Find Seclidemstat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1423715-37-0, Sp-2577, Sp2577, Tyh386v3wj, N-[(e)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide, Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
Molecular Formula
C20H23ClN4O4S
Molecular Weight
450.9  g/mol
InChI Key
MVSQDUZRRVBYLA-HYARGMPZSA-N
FDA UNII
TYH386V3WJ

Seclidemstat
Seclidemstat is an orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.
1 2D Structure

Seclidemstat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
2.1.2 InChI
InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+
2.1.3 InChI Key
MVSQDUZRRVBYLA-HYARGMPZSA-N
2.1.4 Canonical SMILES
CC(=NNC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)C3=C(C=CC(=C3)Cl)O
2.1.5 Isomeric SMILES
C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O
2.2 Other Identifiers
2.2.1 UNII
TYH386V3WJ
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1423715-37-0

2. Sp-2577

3. Sp2577

4. Tyh386v3wj

5. N-[(e)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide

6. Benzoic Acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide

7. Seclidemstat [inn]

8. Unii-tyh386v3wj

9. Seclidemstat [who-dd]

10. Chembl4297641

11. Schembl14697017

12. Schembl14697019

13. (e)-n'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-((4-methylpiperazin-1-yl)sulfonyl)benzohydrazide

14. Ex-a3574

15. Ygc71537

16. Nsc833973

17. S6722

18. Akos037648727

19. Nsc-833973

20. Bs-15371

21. Hy-103713

22. Cs-0039281

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 450.9 g/mol
Molecular Formula C20H23ClN4O4S
XLogP32.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass450.1128541 g/mol
Monoisotopic Mass450.1128541 g/mol
Topological Polar Surface Area111 Ų
Heavy Atom Count30
Formal Charge0
Complexity734
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1423715-37-0 / Seclidemstat API manufacturers, exporters & distributors?

Seclidemstat manufacturers, exporters & distributors 1

62

PharmaCompass offers a list of Seclidemstat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Seclidemstat manufacturer or Seclidemstat supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Seclidemstat manufacturer or Seclidemstat supplier.

PharmaCompass also assists you with knowing the Seclidemstat API Price utilized in the formulation of products. Seclidemstat API Price is not always fixed or binding as the Seclidemstat Price is obtained through a variety of data sources. The Seclidemstat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Seclidemstat

Synonyms

1423715-37-0, Sp-2577, Sp2577, Tyh386v3wj, N-[(e)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide, Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide

Cas Number

1423715-37-0

Unique Ingredient Identifier (UNII)

TYH386V3WJ

About Seclidemstat

Seclidemstat is an orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.

Seclidemstat Manufacturers

A Seclidemstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Seclidemstat, including repackagers and relabelers. The FDA regulates Seclidemstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Seclidemstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Seclidemstat Suppliers

A Seclidemstat supplier is an individual or a company that provides Seclidemstat active pharmaceutical ingredient (API) or Seclidemstat finished formulations upon request. The Seclidemstat suppliers may include Seclidemstat API manufacturers, exporters, distributors and traders.

Seclidemstat GMP

Seclidemstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Seclidemstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Seclidemstat GMP manufacturer or Seclidemstat GMP API supplier for your needs.

Seclidemstat CoA

A Seclidemstat CoA (Certificate of Analysis) is a formal document that attests to Seclidemstat's compliance with Seclidemstat specifications and serves as a tool for batch-level quality control.

Seclidemstat CoA mostly includes findings from lab analyses of a specific batch. For each Seclidemstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Seclidemstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Seclidemstat EP), Seclidemstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Seclidemstat USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty